1. Home
  2. SKYE vs CVU Comparison

SKYE vs CVU Comparison

Compare SKYE & CVU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SKYE
  • CVU
  • Stock Information
  • Founded
  • SKYE 2012
  • CVU 1980
  • Country
  • SKYE United States
  • CVU United States
  • Employees
  • SKYE N/A
  • CVU N/A
  • Industry
  • SKYE Biotechnology: Pharmaceutical Preparations
  • CVU Military/Government/Technical
  • Sector
  • SKYE Health Care
  • CVU Industrials
  • Exchange
  • SKYE Nasdaq
  • CVU Nasdaq
  • Market Cap
  • SKYE 80.7M
  • CVU 70.2M
  • IPO Year
  • SKYE N/A
  • CVU N/A
  • Fundamental
  • Price
  • SKYE $1.44
  • CVU $3.40
  • Analyst Decision
  • SKYE Buy
  • CVU
  • Analyst Count
  • SKYE 6
  • CVU 0
  • Target Price
  • SKYE $16.60
  • CVU N/A
  • AVG Volume (30 Days)
  • SKYE 1.7M
  • CVU 37.4K
  • Earning Date
  • SKYE 05-09-2025
  • CVU 05-14-2025
  • Dividend Yield
  • SKYE N/A
  • CVU N/A
  • EPS Growth
  • SKYE N/A
  • CVU N/A
  • EPS
  • SKYE N/A
  • CVU 0.26
  • Revenue
  • SKYE N/A
  • CVU $81,078,864.00
  • Revenue This Year
  • SKYE N/A
  • CVU N/A
  • Revenue Next Year
  • SKYE N/A
  • CVU N/A
  • P/E Ratio
  • SKYE N/A
  • CVU $13.08
  • Revenue Growth
  • SKYE N/A
  • CVU N/A
  • 52 Week Low
  • SKYE $1.14
  • CVU $2.16
  • 52 Week High
  • SKYE $17.65
  • CVU $5.85
  • Technical
  • Relative Strength Index (RSI)
  • SKYE 40.43
  • CVU 45.19
  • Support Level
  • SKYE $1.26
  • CVU $3.26
  • Resistance Level
  • SKYE $3.73
  • CVU $3.56
  • Average True Range (ATR)
  • SKYE 0.34
  • CVU 0.24
  • MACD
  • SKYE 0.04
  • CVU 0.03
  • Stochastic Oscillator
  • SKYE 11.40
  • CVU 62.50

About SKYE Skye Bioscience Inc. Common Stock

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

About CVU CPI Aerostructures Inc.

CPI Aerostructures Inc is engaged in the manufacturing of structural aircraft parts for fixed-wing aircraft and helicopters in both the commercial and defense markets in the United States. It also provides engineering, program management, supply chain management and kitting, and Maintenance Repair and Overhaul (MRO) services. CPI also acts as a subcontractor to prime aircraft manufacturers in the production of commercial aircraft parts. CPI Aero supplies the E-2D Advanced Hawkeye surveillance aircraft, the A-10 Thunderbolt attack jet, the Gulfstream G650, the UH-60 BLACK HAWK helicopter, and the S-92 helicopter and others.

Share on Social Networks: